Major collaboration! Adicon and Gobroad Medical Group forge in-depth strategic partnership to empower precision diagnosis and treatment for blood and solid tumors

Currently, precision medicine is accelerating its implementation, healthcare system reform continues to deepen, and the industry is moving towards deeper integration of clinical practice and research as well as collaborative innovation between technology and services. The government has been issuing policies encouraging all entities in the medical field to leverage their respective strengths for cross-sector cooperation, promoting the integration and efficient utilization of high-quality medical resources, and comprehensively enhancing the diagnostic capabilities for complex diseases and the level of primary healthcare services.

Against this backdrop, Adicon and Gobroad Medical Group officially signed a strategic cooperation agreement on March 2 at Zhaxin Hospital in Shanghai. Both parties will integrate resources and collaborate deeply based on their core advantages to jointly create an innovative medical ecosystem that combines clinical care with laboratory testing, bringing more hope to patients with serious illnesses and supporting China’s healthcare innovation and development.

According to the agreement, both parties will establish a long-term and stable strategic partnership. The focus will be on conducting diverse collaborations in areas such as medical and scientific research services, co-construction of joint research platforms, information data coordination, academic discipline development, and talent cultivation. Adicon will rely on its nationwide medical testing network and technical reserves to provide comprehensive testing support for Gaobo Medical Group and its affiliated hospitals. Gaobo Medical Group will leverage its clinical diagnosis advantages in complex and severe disease fields, combined with scientific research platform resources, to help Adicon build an innovative chain from clinical discovery to industrial transformation. Both parties will also jointly explore models for co-building regional testing centers and collaborate on in-hospital laboratory departments to promote high-quality testing services that cover grassroots medical institutions more extensively.

▲Signing Ceremony Venue

In this collaboration, Adicon has further clarified its strategic transformation from a 'service provider' to an 'ecosystem co-builder.' As a national chain-operated independent medical laboratory, Adicon not only possesses a nationwide logistics network and professional information systems but has also made substantial breakthroughs in AI healthcare, launching intelligent tools like 'Wenyi Large Model' and 'Ai Xiaoyi.' Based on this technological foundation, Adicon will work closely with Gaobo Medical Group to focus on the integration and innovation of 'AI + Clinical,' pushing artificial intelligence from laboratories into clinics, becoming a reliable intelligent assistant for doctors. Gaobo Medical Group will continue to deepen its position as a 'clinically-driven innovative medical technology platform,' relying on its strong clinical trial research capabilities to provide solid clinical scenarios and data support for the cooperation. The two sides’ combined strengths will enable precise alignment between clinical needs and testing technologies through a joint R&D platform, promoting medical achievements transitioning from labs to clinical applications, truly bridging the 'last mile' from research to industrialization.

At the signing ceremony, Wang Legang, Executive Director, Chief Operating Officer, and General Manager of Adicon, stated in his speech that Adicon and Gaobo’s partnership aims to respond to patients' hopes for life, giving more patients with difficult and severe illnesses hope, and accelerating China's medical innovation. He emphasized that this collaboration is not a simple resource overlay but a deep integration of clinical care and testing, a mutual approach combining innovative ideas with implementation capabilities. He specifically pointed out that by jointly building R&D platforms and a mechanism for transforming results, the ‘source of vitality’ for medical research will be brought faster into frontline clinical settings, allowing medical innovations to truly benefit patients.

▲ Speech by Wang Legang, Executive Director, Chief Operating Officer, and General Manager of Adicon

Mr. Zheng Xiaoyu, CEO of Gaobo Medical Group, said in his speech that Gaobo always adheres to the philosophy of 'putting patients' needs first,' aiming to tackle complex and severe diseases as their medical mission and promote medical innovation as their research mission. He expressed anticipation to work with Adicon through co-building models to push premium medical resources down to grassroots levels, accelerate the application of scientific research achievements in clinical practice, and jointly create a sustainable new model of medical services.

▲ Speech by Mr. Zheng Xiaoyu, CEO of Gaobo Medical Group

This strategic cooperation between Adicon and Gaobo Medical Group represents an important cross-sector fusion between third-party medical testing institutions and research-focused medical groups. It is also a key measure for Adicon to deepen its integrated 'technology + service + ecosystem' development path. Both parties will use a joint R&D platform as the core initiative, focusing on intellectual property co-creation, technological innovation, and mechanisms for transforming achievements, continuously driving clinically driven medical innovation, and truly achieving a closed loop from scientific breakthroughs to clinical value. Standing at this new starting point, both parties will take this collaboration as an opportunity, leveraging professional capabilities and synergistic forces to bring hope to more patients, contribute more specialized strength to the innovation and development of China's medical field, and jointly drive the medical industry towards greater efficiency, precision, and inclusiveness, supporting the construction of a Healthy China.

▲ Representatives of Adicon visit Shanghai Zhaxin Hospital

· About Adicon ·

Adicon, as one of the three major independent medical laboratory (ICL) service providers in China, has been deeply engaged in the medical testing field for many years, committed to continuously providing high-quality testing services to patients and the public, and becoming a trusted and reliable partner for medical professionals and the public.

As a nationwide chain-operated independent medical laboratory, Adicon has built up a medical testing network covering 30 provinces, autonomous regions, and municipalities across the country, reaching over 1,700 cities. It boasts a solid technical reserve of more than 4,000 testing items and over 200 patents, while also maintaining a nationwide logistics network and professional information systems.

Currently, Adicon has wholly acquired Yonde Youqin, a leading enterprise in China’s hematology diagnostics field, as well as CrownBio, a global contract research organization focused on drug discovery, preclinical and translational research, and committed to advancing scientific progress in oncology and immuno-oncology. With three major service platforms—R&D center, clinical trials, and testing services—and six technical centers, Adicon serves approximately 19,000 clients.

· About Gaobo Medical Group ·

Gaobo Medical Group always adheres to the principle of 'Patient Needs First,' pursuing excellence in medical treatment, breakthrough innovations in technology, and creating possibilities for life. It is committed to building an innovative medical technology platform driven by clinical needs.

The group was established in 2017, with business focuses on clinical diagnosis, clinical research, reference laboratories, and informatization. The group collaborates with top medical experts who have extensive clinical experience and research capabilities to build an innovative medical ecosystem encompassing 'clinical discovery-basic research-industrial transformation-clinical application' to improve the efficiency and quality of biopharmaceutical industry development.

Gaobo Group is an explorer of research-oriented hospital models in China. Currently, it operates eight hospitals in Beijing, Shanghai, and Guangzhou, with nearly 1,500 beds available in total. Its focus lies in specialized areas such as solid tumors, hematological diseases, and brain science where innovation thrives. The group also houses Phase I clinical trial wards, central laboratories, early clinical research centers, clinical pharmacology, medicine, and statistics professional service sectors.

With the mission of tackling difficult and critical illnesses, Gaobo provides more treatment options and hope for patients suffering from complex conditions. In terms of promoting medical innovation, Gaobo has already served hundreds of clinical trials for innovative drugs conducted by hundreds of pharmaceutical companies. Medicine advances through encouraging innovation, and innovation shines through embracing medicine.$ADICON HOLDINGS (09860.HK)$

11K Views